The hypothesis that oxidative stress is causative in the development of metabolic disorders, especially insulin-resistant state, has been supported by different studies where treatments reducing ROS production improve insulin sensitivity, hyperlipidemia, and hepatic steatosis [12–14]. This evidence concerns the gene INS and Other metabolic disease.